Showing results (11-20 of 227) with videos related to
Sort By:
Pageof 23
Hematology. American Society of Hematology. Education Program|December 7, 2019
Where does transplant fit in the age of targeted therapies?Victor A Chow, Ajay K GopalClinical Lymphoma, Myeloma & Leukemia|November 10, 2018
Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell LymphomaStephen D Smith, Shruti Gandhy, Ajay K Gopal, et al.The Korean Journal of Hematology|April 6, 2012
Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantationErin-Siobhain R Currin, Ajay K GopalPharmaceuticals (Basel, Switzerland)|March 14, 2017
Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell LymphomaFengting Yan, Ajay K Gopal, Solomon A GrafBlood|June 20, 2018
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphomaVictor A Chow, Mazyar Shadman, Ajay K GopalCancer|May 19, 2023
Safety of loncastuximab tesirine-lpyl in diffuse large B-cell lymphoma with severe hepatic dysfunctionGrace T Baek, Ivan J Huang, Ajay K GopalThe Oncologist|January 11, 2024
A Systematic Review of Clinical Applications of Anti-CD20 Radioimmunotherapy for LymphomaMichael Durando, Ajay K Gopal, Joseph Tuscano, et al.Hemasphere|May 9, 2020
Controversies in the Treatment of Follicular LymphomaKai Hübel, Michele Ghielmini, Marco Ladetto, et al.Blood Advances|May 20, 2026
"Immunologic Dream Team": BiTEs peri-allotransplant to redirect donor lymphocytes towards GVLLorenzo Iovino, Mazyar Shadman, Filippo Milano, et al.British Journal of Haematology|October 10, 2025
Long-term follow-up of dose-dense brentuximab vedotin, ifosfamide, carboplatin and etoposide in second-line treatment of relapsed/refractory classical Hodgkin lymphomaRyan C Lynch, Ryan D Cassaday, Stephen D Smith, et al.Pageof 23